A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma.

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2014
This article has no abstract
Epistemonikos ID: e3e30adffd46c6d95d05c7aa7326059b432cdb17
First added on: Dec 27, 2020